Fc variants and methods for their production

Patent metadata

Field	Value
Publication number	US-10689447-B2
Application number	US-201313958318-A
Country	US
Kind code	B2
Filing date	Aug 2, 2013
Priority date	Feb 4, 2011
Publication date	Jun 23, 2020
Grant date	Jun 23, 2020

Abstract

Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.

First claim

What is claimed is:

1. A heteromultimeric protein or an IgG antibody, wherein the heteromultimeric protein or the IgG antibody each comprises an Fc region comprising substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243 S and (b) F241S and F243R, wherein numbering is according to the EU numbering scheme, wherein no amino acid residue of any Fc polypeptide of the heteromultimeric protein or the IgG antibody is glycosylated, and wherein said heteromultimeric protein or IgG antibody exhibits decreased mispairing, decreased head-to-tail formation or increased overall yield as compared to a heteromultimeric protein or an IgG antibody without said amino acid substitution mutations at residues 241 and 243.

2. The heteromultimeric protein or the IgG antibody of claim 1 , wherein both heavy chains comprise the F241R and F243 S or the F241S and F243R substitutions.

3. A composition comprising the heteromultimeric protein or the IgG antibody of claim 1 and a carrier.

4. The heteromultimeric protein or the IgG antibody of claim 1 wherein the Fc region is an IgG1 Fc region comprising the substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R.

5. The heteromultimeric protein or the IgG antibody of claim 1 , wherein the Fc region further comprises at least one knob-into-hole modification at amino acid residues other than residues 241 and 243, wherein numbering is according to the EU numbering scheme.

6. The heteromultimeric protein or the IgG antibody of claim 5 , wherein the at least one knob-into-hole modification comprises a knob modification comprising a T366W substitution, wherein numbering is according to the EU numbering scheme.

7. The heteromultimeric protein or the IgG antibody of claim 5 , wherein the at least one knob-into-hole modification comprises a hole modification comprising replacing an original amino acid residue from the interface of the Fc region with an amino acid residue with a smaller side chain than the original amino acid residue, wherein the substituting amino acid residue is selected from the group consisting of serine, threonine, valine, and alanine.

8. The heteromultimeric protein or the IgG antibody of claim 7 , wherein the hole modification comprises two or more amino acid substitutions selected from the group consisting of T366S, L368A and Y407V, wherein all numbering is according to the EU numbering scheme.

9. The heteromultimeric protein or the IgG antibody of claim 5 , wherein the Fc region is an IgG1 Fc region comprising the substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R and comprising the at least one knob-into-hole modification.

10. The heteromultimeric protein or the IgG antibody of claim 1 , which is an IgG antibody.

11. The IgG antibody according to claim 10 , wherein the IgG antibody is a multi-specific antibody.

12. The IgG antibody of claim 10 , wherein the IgG antibody comprises an IgG1 Fc region comprising the substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R.

13. An isolated heteromultimeric protein or an isolated IgG antibody produced by culturing a prokaryotic host cell comprising an expression vector encoding the heteromultimeric protein or the IgG antibody, and recovering the heteromultimeric protein or the IgG antibody from the cell culture, wherein the heteromultimeric protein or the IgG antibody each comprises an Fc region comprising substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R, wherein numbering is according to the EU numbering scheme, and wherein no amino acid residue of any Fc polypeptide of the heteromultimeric protein or the IgG antibody is glycosylated.

14. The heteromultimeric protein or the IgG antibody of claim 13 wherein the Fc region is an IgG1 Fc region comprising the substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R.

15. The heteromultimeric protein or the IgG antibody of claim 13 , wherein the prokaryotic host cell is an E. coli cell.

16. The heteromultimeric protein or the IgG antibody of claim 14 , wherein the prokaryotic host cell is an E. coli cell.

17. The heteromultimeric protein or the IgG antibody of claim 13 , wherein the Fc region further comprises at least one knob-into-hole modification at amino acid residues other than residues 241 and 243, wherein numbering is according to the EU numbering scheme.

18. The heteromultimeric protein or the IgG antibody of claim 17 , wherein the at least one knob-into-hole modification comprises a T366W substitution, wherein numbering is according to the EU numbering scheme.

19. The heteromultimeric protein or the IgG antibody of claim 17 , wherein the at least one knob-into-hole modification comprises a hole modification comprising replacing an original amino acid residue from the interface of the Fc region with an amino acid residue with a smaller side chain than the original amino acid residue, wherein the substituting amino acid residue is selected from the group consisting of serine, threonine, valine, and alanine.

20. The heteromultimeric protein or the IgG antibody of claim 19 , wherein the hole modification comprises two or more amino acid substitutions selected from the group consisting of T366S, L368A and Y407V, wherein all numbering is according to the EU numbering scheme.

21. The heteromultimeric protein or the IgG antibody of claim 13 , wherein both heavy chains comprise the F241R and F243 S or the F241S and F243R substitutions.

22. The heteromultimeric protein or the IgG antibody of claim 13 , which is an IgG antibody.

23. The IgG antibody of claim 22 , wherein the IgG antibody comprises an IgG1 Fc region comprising the substitution mutations at residues 241 and 243 on at least one heavy chain, wherein said substitution mutations are selected from the group consisting of (a) F241R and F243S and (b) F241S and F243R.

24. The IgG antibody according to claim 22 , wherein the IgG antibody is a multi-specific antibody.

25. The IgG antibody according to claim 5 , wherein the at least one knob-into-hole modification comprises a knob modification comprising a T366W substitution and a hole modification comprising two or more amino acid substitutions selected from the group consisting of T366S, L368A and Y407V, wherein all numbering is according to the EU numbering scheme.

26. The IgG antibody according to claim 25 , wherein the at least one knob-into-hole modification comprises a knob modification comprising a T366W substitution and a hole modification comprising T366S, L368A and Y407V substitutions, wherein all numbering is according to the EU numbering scheme.

Assignees

• Genentech Inc

Inventors

• Elliott J Michael
• Scheer Justin

Classifications

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/244

  Interleukins [IL] · CPC title

• C07K16/2863 Primary

  against receptors for growth factors, growth regulators · CPC title

• C07K16/247

  IL-4 · CPC title